List of Excipients in Branded Drug IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Generic Drugs Containing IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
WALGREEN COMPANY	ibuprofen and pseudoephedrine hydrochloride	0363-0423	ACACIA
WALGREEN COMPANY	ibuprofen and pseudoephedrine hydrochloride	0363-0423	CALCIUM CARBONATE
WALGREEN COMPANY	ibuprofen and pseudoephedrine hydrochloride	0363-0423	CARNAUBA WAX

What are the Most Frequently-Used Excipients in IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE?

# Of NDCs	Excipient
21	ACACIA
21	CALCIUM CARBONATE
21	CARNAUBA WAX

Ibuprofen and Pseudoephedrine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Ibuprofen and pseudoephedrine hydrochloride is a mature OTC combination with a clear formulation objective: deliver rapid analgesic, antipyretic, and nasal-decongestant effects in one solid oral dose. The strongest commercial opportunities are differentiated caplets, liquid-filled capsules, extended-release products, compliant packaging, and formulations that improve swallowability, stability, and consumer convenience without creating unnecessary regulatory or patent risk.

The combination typically uses ibuprofen as the analgesic and pseudoephedrine hydrochloride as the systemic decongestant. A representative immediate-release strength is ibuprofen 200 mg plus pseudoephedrine hydrochloride 30 mg per dosage unit, as marketed in products such as Advil Cold & Sinus.[1]

What excipient strategy is appropriate for ibuprofen and pseudoephedrine hydrochloride?

The preferred excipient platform depends on the dosage form, target release profile, manufacturing process, and market. Immediate-release tablets and caplets offer the lowest development risk. Liquid-filled capsules and orally disintegrating formats create greater differentiation but require tighter control of compatibility, moisture, taste, and manufacturing cost.

Immediate-release tablet and caplet strategy

A conventional immediate-release formulation may use:

Formulation function	Candidate excipients	Main development purpose
Diluent and compression aid	Microcrystalline cellulose, dibasic calcium phosphate, lactose, mannitol	Improve tablet weight, hardness, and manufacturability
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improve granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Accelerate tablet breakup and drug release
Glidant	Colloidal silicon dioxide	Improve powder flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduce sticking and ejection force
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants	Improve swallowability, identification, and moisture protection
Flavor and sweetener	Limited use in chewable or orally disintegrating formats	Mask taste and improve consumer acceptance

Ibuprofen has low aqueous solubility. The formulation therefore needs efficient disintegration, adequate wetting, and sufficient surface-area exposure. Excessive lubricant, especially magnesium stearate, can reduce wetting and delay dissolution. A short blending time and controlled lubricant addition can reduce this risk.

Pseudoephedrine hydrochloride is water soluble and can dissolve rapidly once the dosage form disintegrates. Its high solubility can create a release imbalance in which pseudoephedrine releases quickly while ibuprofen remains dissolution-limited. Dissolution testing should therefore evaluate each active separately rather than relying only on a combined assay.

Direct compression versus wet granulation

Direct compression can reduce process steps and cost, but it requires consistent flow, particle-size distribution, and segregation control. Ibuprofen is often difficult to process because of poor flow, low compactability, and potential sticking. A formulation based on microcrystalline cellulose, silicified microcrystalline cellulose, or co-processed excipients can improve direct-compression performance.

Wet granulation may provide better content uniformity and tablet robustness but introduces water and drying conditions that can affect:

• Pseudoephedrine distribution and migration.
• Ibuprofen polymorphic or particle-state behavior.
• Residual moisture.
• Coating adhesion.
• Long-term chemical stability.

A dry-granulation or roller-compaction process can be commercially attractive when moisture sensitivity, process throughput, or scale-up risk makes wet granulation less desirable.

What formulations are protected by excipient and dosage-form design?

The most commercially relevant formulation opportunities are not usually based on novel use of the two active ingredients. They arise from release control, physical form, manufacturing process, packaging, or consumer-use improvements.

Liquid-filled softgel or hard capsule

Liquid-filled capsules can improve consumer perception and swallowing. A nonaqueous vehicle may help disperse or solubilize ibuprofen, but pseudoephedrine hydrochloride introduces a formulation challenge because it is more compatible with aqueous or polar systems than with many lipid vehicles.

Potential approaches include:

• A suspension of micronized ibuprofen in a compatible nonaqueous carrier.
• A separate pseudoephedrine-containing fill phase.
• A dual-chamber or bilayer architecture.
• A multiparticulate capsule containing distinct immediate-release pellets.
• A solid or semisolid fill with controlled moisture activity.

These approaches increase development cost and may create new formulation patents, but they also raise manufacturing complexity and stability risk.

Bilayer or multilayer tablet

A bilayer tablet can separate the two active ingredients physically and optimize each release environment. It may also support:

• Immediate-release pseudoephedrine with a slower ibuprofen layer.
• Improved segregation control.
• Different granulation methods for each active.
• Visual product differentiation.

The primary risks are layer adhesion, weight variation, delamination, and higher equipment requirements. A bilayer configuration has commercial value only if it solves a measurable problem, such as dissolution performance, stability, dose flexibility, or manufacturing yield.

Extended-release pseudoephedrine with immediate-release ibuprofen

An extended-release combination can provide longer decongestant coverage while maintaining an immediate analgesic effect. This is technically attractive but carries higher regulatory risk than a conventional immediate-release product because the sponsor must establish release performance for both actives and demonstrate that the combination remains safe and effective under the proposed dosing schedule.

Matrix-forming excipients may include hypromellose, ethylcellulose, methacrylate copolymers, or wax-based systems. The release mechanism must account for pseudoephedrine hydrochloride's high water solubility, which can produce dose dumping or rapid diffusion unless the matrix is carefully designed.

Chewable and orally disintegrating products

Chewable or orally disintegrating products could target consumers who have difficulty swallowing caplets. The main barriers are:

• Bitter or medicinal taste.
• Ibuprofen's relatively high dose burden.
• Pseudoephedrine taste and throat sensation.
• Moisture sensitivity.
• Tablet friability.
• Need for effective taste masking without delaying ibuprofen dissolution.

Mannitol, xylitol, crospovidone, polymeric taste-masking coatings, ion-exchange resins, and flavor systems may be useful. The commercial opportunity is strongest where the dosage unit can remain compact and the product avoids a large number of tablets per dose.

When does ibuprofen and pseudoephedrine lose exclusivity?

The active ingredients are long-established and do not have meaningful basic-molecule exclusivity remaining in the United States. Competition is therefore generally based on OTC monograph compliance, approved product applications, trademarks, packaging, manufacturing capability, and formulation differentiation rather than composition-of-matter patents.

For a standard immediate-release OTC product, the main regulatory route may be compliance with the applicable FDA OTC monograph rather than reliance on an active-ingredient patent. FDA regulations identify permitted active ingredients, indications, warnings, directions, and labeling conditions for OTC analgesic and decongestant products.[2][3]

What is the Orange Book status?

OTC monograph products are not generally protected through the same Orange Book patent-listing structure used for approved prescription products. FDA's Orange Book is primarily a listing of approved drug products and therapeutic-equivalence information, including patents and exclusivity associated with applicable approved applications.[4]

A branded ibuprofen-pseudoephedrine product may have:

• No relevant Orange Book-listed patent if marketed under the OTC monograph pathway.
• Application-specific patents if approved under an NDA.
• Private formulation, process, packaging, trademark, or trade-secret protection.
• Patent rights that do not block all competing immediate-release products.

The absence of an Orange Book patent does not mean the product has no intellectual-property protection. It means that the principal competitive barrier may sit outside the conventional Orange Book Paragraph IV framework.

Which patent and litigation risks affect generic entry?

The core active ingredients present limited patent risk because both are established generic substances. The more relevant risks concern product-specific formulation or delivery technology.

Paragraph IV challenges

A Paragraph IV certification applies when a generic applicant challenges a listed patent for an approved drug application. It is most relevant where the branded product has an approved NDA and Orange Book-listed patents. It is less central for a product marketed under the OTC monograph system without listed patents.

A generic applicant may instead enter by:

1. Following the applicable OTC monograph.
2. Filing an abbreviated or full NDA where required.
3. Launching a different formulation that avoids an asserted formulation patent.
4. Using a distinct trade dress and packaging system.
5. Competing through private-label or retailer-branded distribution.

Formulation patent exposure

Potentially relevant claims may cover:

• Specific ibuprofen-to-pseudoephedrine ratios.
• Extended-release release profiles.
• Liquid-filled capsule compositions.
• Multiparticulate or bilayer structures.
• Taste-masking systems.
• Low-moisture formulations.
• Stabilized suspensions.
• Manufacturing processes.
• Unit-dose packaging that limits moisture or tampering.

The strength of such patents depends on claim breadth, prior-art disclosure, enablement, written description, and whether the claims require a commercially unusual excipient combination. Broad claims covering a conventional tablet with standard excipients are generally more vulnerable than narrowly defined release or process claims supported by robust comparative data.

Litigation and settlement status

No single litigation or settlement position can be assigned to the entire ibuprofen-pseudoephedrine category. Litigation risk must be assessed against the specific brand, NDA, patent number, dosage form, and proposed generic product. Mature OTC products commonly face competition from store brands and private-label manufacturers without a public Paragraph IV settlement structure.

How should excipients support FDA regulatory compliance?

FDA-compliant excipient selection requires more than confirming that each ingredient is individually accepted. The complete formulation must support safety, quality, stability, and finished-product performance.

Key controls include:

• Use of excipients with appropriate compendial or regulatory status.
• Control of elemental impurities, residual solvents, microbial quality, and peroxide content.
• Compatibility studies between ibuprofen, pseudoephedrine hydrochloride, coating materials, and lubricants.
• Dissolution testing for each active.
• Assay and content-uniformity testing across the shelf life.
• Moisture sorption and packaging studies.
• Extractables and leachables evaluation for liquid-filled systems.
• Photostability and temperature-humidity stability.
• Evaluation of nitrosamine risk where relevant to excipient, process, or packaging inputs.

The finished product must also carry appropriate warnings for NSAID use, hypertension and cardiovascular risks, gastrointestinal bleeding, renal risks, and pseudoephedrine-related contraindications and precautions. Labeling requirements are governed by the applicable FDA monograph, approved labeling, and product-specific regulatory pathway.[2][3]

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are operational rather than molecule-specific.

High-value manufacturing controls

Barrier	Commercial impact
Ibuprofen sticking during compression	Lower tablet yield, tooling wear, production downtime
Segregation between the two active ingredients	Content-uniformity failures and batch rejection
Moisture uptake	Stability loss, poor coating, capsule deformation
Slow ibuprofen dissolution	Failure against specification or performance target
Pseudoephedrine migration in granulation	Dose variation and stability problems
Pseudoephedrine diversion controls	Limits packaging, distribution, and retail channels
High tablet weight	Poor swallowability and lower consumer preference
Coating defects	Reduced appearance, stability, and brand differentiation

Pseudoephedrine is regulated as a List I chemical under U.S. federal controls. Retail sales, mail-order transactions, identification requirements, recordkeeping, and purchase limits affect inventory planning and packaging strategy.[5] The product's commercial opportunity is therefore linked to compliant distribution as much as to formulation performance.

What commercial opportunities exist for ibuprofen and pseudoephedrine products?

Convenience-led products

The most defensible near-term opportunity is a compact product that combines cold-symptom relief and pain relief in one dosage unit. A caplet with improved swallowability, clear symptom positioning, and tamper-evident packaging can compete without requiring novel pharmacology.

Private-label and retailer products

Because the active ingredients are mature, retailers can compete on:

• Lower price.
• Smaller pack sizes.
• Seasonal promotions.
• Club-store multipacks.
• E-commerce availability.
• Distinct dosage forms.
• Child-resistant or senior-friendly packaging.

A contract manufacturer with validated content-uniformity, coating, and packaging capabilities can support multiple retailer brands from one platform.

Travel and single-dose packaging

Unit-dose blister packs and small cartons can target travel, workplace, and emergency-use occasions. The principal value is portability and dosing clarity. Packaging must account for child-resistant requirements, tamper evidence, moisture protection, and pseudoephedrine transaction controls.

Combination-product line extensions

Commercial extensions may include:

• Ibuprofen-pseudoephedrine immediate-release caplets.
• Extended-release pseudoephedrine with immediate-release ibuprofen.
• Liquid-filled capsules.
• Nighttime variants, subject to appropriate active-ingredient and labeling review.
• Lower-dose products for consumers seeking reduced exposure.
• Products with reduced tablet burden.
• Seasonal family packs.

A nighttime product introduces additional safety and regulatory considerations if sedating ingredients are added. It should not be treated as a simple excipient or packaging extension.

How does this product compare with competing cold and pain combinations?

Product category	Main value proposition	Formulation complexity	Key commercial risk
Ibuprofen plus pseudoephedrine	Pain, fever, and congestion relief	Moderate	Pseudoephedrine controls and cardiovascular warnings
Acetaminophen plus pseudoephedrine	Pain, fever, and congestion relief without NSAID exposure	Low to moderate	Acetaminophen liver-warning positioning
Ibuprofen alone	Analgesia and fever reduction	Low	No decongestant benefit
Pseudoephedrine alone	Nasal decongestion	Low	Limited symptom coverage and sales restrictions
Phenylephrine combinations	Decongestion positioning with fewer sales controls	Low to moderate	FDA effectiveness concerns for oral phenylephrine have affected the category
Multi-symptom cold products	Broad symptom coverage	Moderate to high	Higher active count, warning complexity, and medication-error risk

The ibuprofen-pseudoephedrine combination has a focused clinical proposition. It can be easier to position than a broad multi-symptom product, but the product excludes consumers who should avoid NSAIDs or systemic sympathomimetics.

What geographic opportunities exist?

The United States offers strong familiarity with the combination but imposes pseudoephedrine sales controls. European, Canadian, and other markets differ in:

• OTC versus prescription status.
• Permitted pseudoephedrine dose.
• Maximum pack size.
• Advertising rules.
• NSAID warnings.
• Pediatric labeling.
• Excipient restrictions.
• Trademark availability.
• Market authorization pathway.

A global excipient strategy should avoid assuming that a U.S. monograph formulation can be transferred directly to other jurisdictions. The same combination may require separate regulatory submissions, revised warnings, different pack sizes, or substitution of colorants and excipients.

Is biosimilar risk relevant to ibuprofen and pseudoephedrine?

No. Ibuprofen and pseudoephedrine hydrochloride are small-molecule active ingredients, not biologics. Biosimilar pathways do not apply. Competitive entry is based on generic-drug, OTC monograph, NDA, private-label, and formulation-specific routes.

How strong is the patent estate for this product category?

The category's core patent estate is generally weak because the active ingredients and basic therapeutic combination are old. Patent strength can still be moderate for a narrowly differentiated product with:

• A validated extended-release profile.
• A non-obvious multiparticulate design.
• A technically difficult liquid-filled formulation.
• A manufacturing process that materially improves quality or yield.
• A credible stability advantage.
• A commercially useful taste-masking or swallowability system.

The strongest commercial moat is likely to combine formulation know-how, validated manufacturing, regulatory execution, packaging compliance, trademarks, and retailer relationships. A conventional tablet using standard excipients is more exposed to private-label competition.

Key Takeaways

• The lowest-risk development route is an immediate-release tablet or caplet using standard, well-characterized excipients.
• Ibuprofen's low solubility and compression behavior should drive disintegration, wetting, granulation, and lubricant optimization.
• Pseudoephedrine hydrochloride's high solubility creates a need to control release balance and content uniformity.
• The active ingredients have little meaningful basic-molecule exclusivity remaining.
• OTC monograph compliance, private-label competition, and product-specific formulation rights are more important than a conventional Orange Book patent estate.
• Liquid-filled capsules, bilayer tablets, extended-release designs, and unit-dose packaging offer the clearest differentiation opportunities.
• Pseudoephedrine sales controls affect packaging, distribution, inventory, and channel economics.
• Biosimilar risk is not applicable.
• The strongest commercial strategy combines a compact dosage form, rapid and reproducible dissolution, compliant packaging, and a low-cost scalable manufacturing process.

FAQs

Can ibuprofen and pseudoephedrine hydrochloride be formulated in the same tablet?

Yes. Immediate-release combination tablets and caplets are technically feasible, but development must control segregation, ibuprofen dissolution, pseudoephedrine content uniformity, lubricant effects, and moisture exposure.

Which excipient is best for improving ibuprofen dissolution?

No single excipient is universally optimal. Disintegrants, wetting aids, particle-size control, surfactants where justified, and granulation design generally have a greater effect than simply increasing tablet porosity.

Does pseudoephedrine require special packaging?

Yes. U.S. products must account for federal and state controls on retail sales, identification, recordkeeping, purchase limits, and diversion prevention. Packaging and distribution design should be developed with those requirements in mind.[5]

Can an OTC manufacturer obtain patent protection for a new ibuprofen-pseudoephedrine tablet?

Yes, if the formulation or process satisfies patentability requirements. Protection is more credible for a technically differentiated release system, multiparticulate architecture, stability solution, or manufacturing process than for a conventional tablet using routine excipients.

Is an ibuprofen-pseudoephedrine product automatically therapeutically equivalent to a branded product?

No. Therapeutic equivalence depends on the regulatory pathway, dosage form, strength, release characteristics, labeling, and applicable FDA requirements. OTC monograph compliance does not eliminate the need to establish product quality and regulatory conformity.

References

1. DailyMed. (n.d.). Advil Cold and Sinus: Ibuprofen and pseudoephedrine hydrochloride tablet, film coated. U.S. National Library of Medicine.
2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use.
3. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Drug Enforcement Administration. (n.d.). Products containing pseudoephedrine, ephedrine, and phenylpropanolamine: Retail sales requirements.